High dose adenosine in acute myocardial infarction study

High dose adenosine in acute myocardial infarction study - Hammer 2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31451

Enrollment

Registered

2007-12-21

Start date

2008-09-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction heart attack

Interventions

Intravenous Adenosine 140 µg/kg per min during the course of the PCI (appr. 1 hour)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with acute myocardial infarction with clinical indication for primary PCI. Symptoms of myocardial ischemia less then 6 hours (12 hours in case of anterior infarction with persistent complaints).

Exclusion criteria

Exclusion criteria: history of myocardial infarction history of heart surgery obstructive lungdisease second degree AV-block. pregnant women contra-indication for MRI impossibility to give informed consent

Design outcomes

Primary

Measure	Time frame
Infarct size and no-reflow zone on CE-MRI 3 months after index PCI	—

Secondary

Measure	Time frame
ST-segment resolution, angiographic parameters, enzymatic infarctsize, ventricular function, clinical parameters	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)